Faculty: Mark Lebwohl, MD

Psoriasis is a chronic, immune-mediated, multi-system inflammatory skin disease conventionally treated with topical corticosteroids and assorted systemic medications including biologics. Rapid expansion in psoriasis treatment options holds great promise for patients with psoriasis who continue to struggle with symptoms or feel dissatisfied with treatment options. Join Mark Lebwohl, MD, as he discusses the availability of novel agents and the differences among these agents and their appropriate clinical use among patients with psoriasis.

At the end of this podcast, participants will be able to:

• Define the role of IL-17A and IL-17F inhibitors across multiple disease pathways and how therapies target this pathway.
• Understand the benefit-risk profiles of IL-17 inhibitors across multiple inflammatory diseases.
• Discuss the differences between IL-17 inhibitors for the management of multiple inflammatory disease states.
• Describe strategies on how to individualize care for their patients with IL-17 inhibitors.